Publication date: Jul 09, 2025
The company’s robust patent portfolio and collaborations with leading research institutions reinforce its leadership in NAD+ science and healthy aging research. This exclusive worldwide license allows Niagen to develop and commercialize its patented nicotinamide riboside (Niagen) as a potential therapy for Parkinson’s disease.
| Concepts | Keywords |
|---|---|
| Bioscience | Agreement |
| Ceo | Bioscience |
| Exclusive | Clinical |
| Norway | Develop |
| Parkinson | Disease |
| Exclusive | |
| Haukeland | |
| Hospital | |
| Nad+ | |
| Niagen | |
| Nopark | |
| Norway | |
| Parkinson | |
| Therapy | |
| Trial |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Parkinson’s disease |
| disease | MESH | disease progression |
| disease | MESH | neurodegenerative diseases |
| pathway | REACTOME | Neurodegenerative Diseases |
Original Article
(Visited 21 times, 1 visits today)